HomeCompareTALS vs KMB

TALS vs KMB: Dividend Comparison 2026

TALS yields 55.51% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TALS wins by $475.7K in total portfolio value
10 years
TALS
TALS
● Live price
55.51%
Share price
$2.72
Annual div
$1.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$521.6K
Annual income
$114,803.66
Full TALS calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — TALS vs KMB

📍 TALS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTALSKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TALS + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TALS pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TALS
Annual income on $10K today (after 15% tax)
$4,718.75/yr
After 10yr DRIP, annual income (after tax)
$97,583.11/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, TALS beats the other by $93,144.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TALS + KMB for your $10,000?

TALS: 50%KMB: 50%
100% KMB50/50100% TALS
Portfolio after 10yr
$283.8K
Annual income
$60,013.00/yr
Blended yield
21.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

TALS
Analyst Ratings
2
Buy
3
Hold
Consensus: Hold
Altman Z
5.6
Piotroski
1/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TALS buys
0
KMB buys
0
No recent congressional trades found for TALS or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTALSKMB
Forward yield55.51%5.25%
Annual dividend / share$1.51$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$521.6K$45.9K
Annual income after 10y$114,803.66$5,222.34
Total dividends collected$425.9K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold

Year-by-year: TALS vs KMB ($10,000, DRIP)

YearTALS PortfolioTALS Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$16,251$5,551.47$11,314$614.45+$4.9KTALS
2$25,821$8,431.73$12,867$760.19+$13.0KTALS
3$40,148$12,520.17$14,713$945.27+$25.4KTALS
4$61,153$18,193.88$16,924$1,181.90+$44.2KTALS
5$91,333$25,899.34$19,596$1,486.64+$71.7KTALS
6$133,877$36,150.61$22,850$1,882.16+$111.0KTALS
7$192,771$49,523.37$26,849$2,399.80+$165.9KTALS
8$272,910$66,644.47$31,812$3,083.36+$241.1KTALS
9$380,191$88,177.34$38,033$3,994.72+$342.2KTALS
10$521,608$114,803.66$45,918$5,222.34+$475.7KTALS

TALS vs KMB: Complete Analysis 2026

TALSStock

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

Full TALS Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this TALS vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TALS vs SCHDTALS vs JEPITALS vs OTALS vs KOTALS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.